PL2328858T3 - Napój zawierający ester hydroksymaślanu i jego zastosowanie medyczne - Google Patents

Napój zawierający ester hydroksymaślanu i jego zastosowanie medyczne

Info

Publication number
PL2328858T3
PL2328858T3 PL09789596T PL09789596T PL2328858T3 PL 2328858 T3 PL2328858 T3 PL 2328858T3 PL 09789596 T PL09789596 T PL 09789596T PL 09789596 T PL09789596 T PL 09789596T PL 2328858 T3 PL2328858 T3 PL 2328858T3
Authority
PL
Poland
Prior art keywords
drink
medical use
hydroxybutyrate ester
hydroxybutyrate
ester
Prior art date
Application number
PL09789596T
Other languages
English (en)
Polish (pl)
Inventor
Kieran Clarke
Richard Lewis Veech
Original Assignee
Oxford University Innovation Limited
The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Limited, The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services filed Critical Oxford University Innovation Limited
Publication of PL2328858T3 publication Critical patent/PL2328858T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/675Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Polymers & Plastics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL09789596T 2008-08-21 2009-04-16 Napój zawierający ester hydroksymaślanu i jego zastosowanie medyczne PL2328858T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9075108P 2008-08-21 2008-08-21
EP09789596.5A EP2328858B1 (en) 2008-08-21 2009-04-16 Drink comprising hydroxybutyrate ester and medical use thereof
PCT/US2009/040766 WO2010021766A1 (en) 2008-08-21 2009-04-16 Hydroxybutyrate ester and medical use thereof

Publications (1)

Publication Number Publication Date
PL2328858T3 true PL2328858T3 (pl) 2018-06-29

Family

ID=40885956

Family Applications (2)

Application Number Title Priority Date Filing Date
PL09789596T PL2328858T3 (pl) 2008-08-21 2009-04-16 Napój zawierający ester hydroksymaślanu i jego zastosowanie medyczne
PL17176132T PL3296284T3 (pl) 2008-08-21 2009-04-16 Nieterapeutyczne zastosowanie estru hydroksymaślanowego

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL17176132T PL3296284T3 (pl) 2008-08-21 2009-04-16 Nieterapeutyczne zastosowanie estru hydroksymaślanowego

Country Status (10)

Country Link
EP (3) EP2328858B1 (cg-RX-API-DMAC7.html)
JP (2) JP5773870B2 (cg-RX-API-DMAC7.html)
CN (1) CN102164884B (cg-RX-API-DMAC7.html)
AU (1) AU2009283171B2 (cg-RX-API-DMAC7.html)
CA (1) CA2734720C (cg-RX-API-DMAC7.html)
DK (2) DK3296284T3 (cg-RX-API-DMAC7.html)
ES (2) ES2907630T3 (cg-RX-API-DMAC7.html)
NO (1) NO2328858T3 (cg-RX-API-DMAC7.html)
PL (2) PL2328858T3 (cg-RX-API-DMAC7.html)
WO (1) WO2010021766A1 (cg-RX-API-DMAC7.html)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1648952T3 (en) 2003-06-03 2018-05-28 The Us Gov As Represented By The Department Of Health And Human Services Dietary supplements and therapeutic compositions comprising (R) -3-hydroxybutyrate derivatives
DK2240017T3 (da) 2008-01-04 2019-06-17 Univ Oxford Innovation Ltd Ketonlegemer og ketonlegemsestere som blodlipid-sænkende midler
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
GB201002983D0 (en) 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
US8329938B2 (en) * 2011-02-21 2012-12-11 Eastman Chemical Company Hydroxyalkanoic acid and hydroxyalkanoice acid oligomer esters of retinol
GB201206192D0 (en) * 2012-04-05 2012-05-23 Tdeltas Ltd Ketone bodies and ketone body esters and for maintaining or improving muscle power output
ES2752030T3 (es) * 2012-11-05 2020-04-02 Us Health Cuerpos cetónicos para proteger los tejidos del daño por radiación ionizante
GB201304467D0 (en) * 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin
CA2905225C (en) 2013-03-14 2021-05-04 Isis Innovation Limited Process for producing (r)-3-hydroxybutyl (r)-3-hydroxybutyrate
GB201314127D0 (en) * 2013-08-07 2013-09-18 Tdeltas Ltd Ketone body and ketone body ester for reducing muscle breakdown
EP3549928B1 (en) * 2014-01-13 2021-09-22 University of South Florida Methods of sustaining dietary ketosis and its effects on muscle fatigue
CN103860533A (zh) * 2014-02-12 2014-06-18 新乡医学院 β羟基丁酸在治疗帕金森病中的应用
CN106456686A (zh) * 2014-03-19 2017-02-22 斯坦陵布什大学 用于治疗或增强肌肉组织的方法
US10245242B1 (en) * 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
SG11201809211QA (en) * 2016-04-19 2018-11-29 Keto Patent Group Inc Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US11026929B2 (en) 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
MX385367B (es) 2016-06-07 2025-03-18 The J David Gladstone Inst Esteres de acidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y metodos para usar los mismos.
US20180057846A1 (en) 2016-08-30 2018-03-01 KetoneAid Inc. Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy
MX390420B (es) * 2016-12-23 2025-03-20 Univ Leuven Kath 3-hidroxibutirato solo o en combinación para su uso en el tratamiento de cuidados intensivos.
US12171735B2 (en) 2017-04-19 2024-12-24 Axcess Global Sciences, Llc Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans
GB201710229D0 (en) * 2017-06-27 2017-08-09 Tdeltas Ltd Compounds for new use
EP3654963A4 (en) * 2017-07-21 2021-04-14 Buck Institute for Research on Aging BETA-HYDROXYBUTYRATE AND BUTANEDIOL S ENANTIOMERS AND THEIR METHODS OF USE
US11760963B2 (en) 2017-08-23 2023-09-19 KetoneAid Inc. Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol
GB201715654D0 (en) 2017-09-27 2017-11-08 Tdeltas Ltd Method of treatment
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US12037317B2 (en) 2018-01-25 2024-07-16 Buck Institute For Research On Aging Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds
GB2572185A (en) * 2018-03-21 2019-09-25 Chain Biotechnology Ltd Pharmaceutical compositions
GB2575623B (en) * 2018-06-04 2022-10-26 Tdeltas Ltd 3-hydroxybutyrate esters for treating cancer cachexia
CA3022995C (en) * 2018-06-12 2019-10-15 Ketofibe (9211-3133 Quebec Inc.) Novel ketogenic compounds, compositions, methods and use thereof
US20210267251A1 (en) * 2018-06-21 2021-09-02 Societe Des Produits Nestle S.A. Compositions and methods using a nicotinamide adenine dinucleotide (nad+) precursor and at least one ketone or ketone precursor
GB2577723A (en) * 2018-10-04 2020-04-08 Tdeltas Ltd Compounds for new use
CN113329992B (zh) * 2019-01-17 2024-04-30 凯托利皮克斯治疗有限责任公司 基于多元醇的羟基羧酸酯的生产方法
CN109700021A (zh) * 2019-03-04 2019-05-03 清华大学 3-羟基丁酸及其衍生物在制备预防和治疗肥胖及肥胖相关疾病的产品中的应用
BR112021021557A2 (pt) 2019-05-10 2021-12-28 Ketoswiss Ag Corpos de cetona confinados em microesferas
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
WO2020234348A1 (en) * 2019-05-21 2020-11-26 Société des Produits Nestlé S.A. Dietary butyrate
CN114008015B (zh) * 2019-06-12 2024-02-20 凯托利皮克斯治疗有限责任公司 羟基羧酸多元醇酯、特别是聚甘油酯的制备方法
US20250197566A1 (en) * 2019-06-12 2025-06-19 Ioi Oleo Gmbh Process for preparing polyol-based esters of acyl-capped hydroxy carboxylic acids
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
WO2021195477A1 (en) * 2020-03-27 2021-09-30 Ketoneaid, Inc. Ketone ester as a therapeutic treatment of covid-19, long covid, and related viral infections
US20230174454A1 (en) * 2020-05-12 2023-06-08 Genomatica, Inc. Process of synthesizing and purifying (3r)-hydroxybutyl (3r)-hydroxybutanoate
WO2022012767A1 (de) * 2020-07-13 2022-01-20 Ioi Oleo Gmbh Verfahren zur herstellung von polyglycerinestern von mit oxobutanol veresterten polycarbonsäuren
US20240228422A1 (en) * 2020-07-13 2024-07-11 Ioi Oleo Gmbh Process for preparing oxobutanol esters of polymeric carboxylic acids
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
CN113045416B (zh) * 2021-03-23 2023-08-18 南京纽邦生物科技有限公司 一种(r)-3-羟基丁酰-(r)-3-羟基丁酯的制备方法
US20240342121A1 (en) * 2021-07-09 2024-10-17 Georgia State University Research Foundation, Inc. The use of beta-hydroxybutyrates for the treatment or prevention of aneurysms and dissections
CA3219283A1 (en) 2021-07-17 2023-01-26 Elena GROSS Combination of a ketone body or ketogenic compound with an analgesic or antioxidant
IT202100020441A1 (it) 2021-07-30 2023-01-30 Unichem Estense S R L Miscela di un mono-estere e un di-estere, in cui detti mono-estere e di-estere sono esteri dell’acido (R)-3-idrossibutanoico con un polialcol, processo per la preparazione della miscela e relativi usi medici

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1051853B (it) * 1975-01-07 1981-05-20 Basf Ag Butandiol 1.3 3 mono 3 idros sibutirrati butandiol 1.3 1mono 3 idrossibutirrati e processi per la loro preparazione
JPH0755158B2 (ja) * 1986-10-30 1995-06-14 チッソ株式会社 光学活性エステルの製造法
BE1001209A3 (fr) * 1987-11-19 1989-08-22 Solvay Compositions pharmaceutiques contenant un derive de l'acide 3-hydroxybutanoique choisi parmi les oligomeres de cet acide et les esters de cet acide ou de ces oligomeres avec du 1,3-butanediol.
JP4598203B2 (ja) * 1995-12-01 2010-12-15 ビーティージー・インターナショナル・リミテッド 脳機能改善剤
WO2004105742A1 (en) 2003-06-02 2004-12-09 Isis Innovation Limited Treatment of muscle fatigue
DK1648952T3 (en) 2003-06-03 2018-05-28 The Us Gov As Represented By The Department Of Health And Human Services Dietary supplements and therapeutic compositions comprising (R) -3-hydroxybutyrate derivatives
WO2007063037A2 (de) * 2005-11-29 2007-06-07 Basf Se Verfahren zur um- oder veresterung von seitenketten in polymeren
US8452351B2 (en) * 2008-06-02 2013-05-28 Qualcomm Incorporated Methods and apparatus for saving battery power in mobile stations

Also Published As

Publication number Publication date
EP4011374A1 (en) 2022-06-15
CN102164884B (zh) 2015-03-11
CA2734720A1 (en) 2010-02-25
EP2328858A1 (en) 2011-06-08
PL3296284T3 (pl) 2022-06-13
JP6092836B2 (ja) 2017-03-08
JP2015057427A (ja) 2015-03-26
EP2328858B1 (en) 2017-10-11
EP3296284A1 (en) 2018-03-21
CA2734720C (en) 2017-07-18
AU2009283171B2 (en) 2014-08-14
ES2655367T3 (es) 2018-02-19
HK1159604A1 (en) 2012-08-03
AU2009283171A1 (en) 2010-02-25
DK3296284T3 (da) 2022-02-28
EP3296284B1 (en) 2021-12-01
JP5773870B2 (ja) 2015-09-02
DK2328858T3 (en) 2018-01-15
NO2328858T3 (cg-RX-API-DMAC7.html) 2018-03-10
CN102164884A (zh) 2011-08-24
JP2012500264A (ja) 2012-01-05
ES2907630T3 (es) 2022-04-25
WO2010021766A1 (en) 2010-02-25

Similar Documents

Publication Publication Date Title
PL2328858T3 (pl) Napój zawierający ester hydroksymaślanu i jego zastosowanie medyczne
EP2240231A4 (en) MULTIFUNCTION CATHETER AND ITS USE
EP2367444A4 (en) MEDICAL AND NUTRITIONAL FORMULATIONS
EP2022512A4 (en) CATHETER HOSE AND CATHETER WITH HOSE
SG10201801503XA (en) e-POLYLYSINE CONJUGATES AND USE THEREOF
EP2218433A4 (en) MEDICAL CONTAINER AND SET OF MEDICAL CONTAINERS
HUE041034T2 (hu) SAP-variánsok és alkalmazásuk
IL208771A0 (en) Iminopyridine derivatives and use thereof
ZA201104161B (en) Dihydroetorphines and their preparation
GB0920258D0 (en) New medical agents and use thereof
ZA201201676B (en) Azetidinone compounds and medical use thereof
AP3650A (en) Apolipoprotein l-i variants and their use
GB2460181B (en) Depsipeptides and their therapeutic use
GB2460178B (en) Depsipeptides and their therapeutic use
IL208824A0 (en) Iminopyridine derivative and use thereof
GB0905970D0 (en) Depsipeptides and their therapeutic use
GB2460180B (en) Depsipeptides and their therapeutic use
GB0813359D0 (en) Halfin and/or platerfin
GB0812734D0 (en) MEdical compsoitions and devices
EP2349441A4 (en) CATHETER AND METHODS FOR VALVULOPLASTY
GB0906993D0 (en) Combination coffin and furniture
HK1159434A (en) Medical and nutritional formulations
GB0905776D0 (en) Shelf bracket and shelf
GB0809324D0 (en) Depsipeptides and their therapeutic use
GB0809328D0 (en) Depsipeptides and their therapeutic use